Enzymatica AB (publ) (ENZY.ST) Research

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.

Market snapshot

Symbol
ENZY.ST
Price
$2.52
Day change
+0.80%
Market cap
$611.7M
P/E ratio
-12.92x
52-week range
1.6-3.4
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 24 days

Peer companies

  • Ascelia Pharma AB (publ) (ACE.ST)
  • AlzeCure Pharma AB (publ) (ALZCUR.ST)
  • Corline Biomedical AB (CLBIO.ST)
  • Enorama Pharma AB (publ) (ERMA.ST)
  • FluoGuide A/S (FLUO.ST)
  • Mendus AB (publ) (IMMU.ST)
  • Magle Chemoswed Holding AB (publ) (MAGLE.ST)
  • Moberg Pharma AB (publ) (MOB.ST)

Open Enzymatica AB (publ) (ENZY.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.